Status:
UNKNOWN
"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."
Lead Sponsor:
Aga Khan University
Collaborating Sponsors:
Rehman Medical Institute - RMI
Conditions:
Diabetes Mellitus, Type 2
Weight Change, Body
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
A prospective interventional trial for 9 months will be carried out on 300 type-2 diabetes mellitus volunteer patients who are above 18-year-old and participants will be selected through consecutive s...
Detailed Description
Patients will be recruited from all the 12 centers included in the trial across Pakistan and data will be electronically transferred to the main center. All GLP-1 naive patients fulfilling the inclusi...
Eligibility Criteria
Inclusion
- Both male and female Type 2 Diabetic patients with age ≥18 years.
- Patients with HbA1c ≥ 7.5 % - ≤ 10.0%
- Patients with BMI ≥ 30
Exclusion
- Patients with Type 1 Diabetes Mellitus
- Patients with Gestational Diabetes Mellitus.
- Patients with Chronic Renal Failure with eGFR of ≤ 30ml/min
- Patient already on another GLP 1 analogue
- The patient stopped any GLP1 analogue treatment less than 3 months back.
- Patients with history of chronic pancreatitis or pancreatic cancer.
Key Trial Info
Start Date :
March 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05249881
Start Date
March 10 2022
End Date
December 1 2022
Last Update
August 5 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rehman Medical Institute
Peshawar, KPK, Pakistan, 25100
2
Aga Khan University
Karachi, Sindh, Pakistan, 74800